DFO
COGT icon

Duquesne Family Office’s Cogent Biosciences COGT Stock Holding History

Duquesne Family Office’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,214,470
Closed -$78.7M – 76
2025
Q4 		$78.7M Buy
2,214,470
+1,154,890
+109% +$32.5M 1.75% 18
2025
Q3 		$15.2M Buy
+1,059,580
New +$12.6M 0.37% 56

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Duquesne Family Office's COGT Position: Q1 2026 in Review

Duquesne Family Office sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 2,214,470 shares — an estimated $78.7M sold.

Duquesne Family Office first reported a position in COGT in Q3 2025 and held it in 2 quarters. The position peaked at $78.7M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Duquesne Family Office reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
  • Duquesne Family Office sold 2,214,470 Cogent Biosciences shares in Q1 2026, an estimated $78.7M.
  • Duquesne Family Office first reported a position in Cogent Biosciences in Q3 2025 and held it in 2 quarters.
  • Duquesne Family Office's Cogent Biosciences position peaked at $78.7M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Duquesne Family Office's 13F filing for Q1 2026, filed 15 May 2026.